A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax BGB11417-108

• Research type

  Research Study

• Full title

  A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies.

• IRAS ID

  1011356

• Contact name

  Mandeep Kalia

• Contact email

  RegEU@BeiGene.com

• Sponsor organisation

  Beigene Ltd

• Eudract number

  2024-518829-15

• Clinicaltrials.gov Identifier

  NCT06697184

• Research summary

  A study to test the safety of novel methods of gradually increasing the dose of Sonrotoclax in adults with blood cancers.

• REC name

  North East - Tyne & Wear South Research Ethics Committee

• REC reference

  25/NE/0039

• Date of REC Opinion

  28 Mar 2025

• REC opinion

  Further Information Favourable Opinion